

## Overview

Vivia Biotech can significantly enhance AML drug profiling processes thanks to our access to biological samples from real patients.


## AML Assays in Primary Patient Samples

Vivia Biotech has access to primary samples from patients diagnosed with a variety of hematological malignancies including AML and can provide extremely valuable data making the difference in your drug development pipeline.

### Diagnostic & Relapse/Refractory Samples Availability

Click  to learn more

Click  for custom assays in solid tumors

Click  for custom assays in hematological malignancies



#### Fresh samples

- 👍 6,000 patient samples across Hem Malignancies
- 👍 2,000 AML samples evaluated
- 👍 60-100 fresh AML samples received annually



#### Preserved samples

- 👍 600 AML samples in stock



#### Clinical information available

- ✓ Patient demographics
- ✓ Malignancy diagnosis date and subtype classification
- ✓ Previously administered treatments and drugs

Santiago Grisolia 2  
28760 . Madrid . Spain  
(+34) 91 129 3151  
admin@viviabiotech.com


www.viviabiotech.com

Overview

Vivia Biotech can significantly enhance AML drug profiling processes thanks to our access to biological samples from real patients.

Click  to learn more


Click  for custom assays in solid tumors

Click  for custom assays in hematological malignancies

## Vivia AML Ex Vivo Assays in a Nutshell...

We have specific assays to cover the different mechanisms of action of many drugs and compounds and to capture the effects of apoptosis, necrosis, cell cycle arrest, proliferation, immune cell modulation, or antibody-dependent cellular cytotoxicity, between others, directly on patient samples.

Our key innovations supply sound pharmacology using real AML patient samples.



Santiago Grisolia 2

28760 . Madrid . Spain

(+34) 91 129 3151

admin@viviabiotech.com


www.viviabiotech.com

## Overview

Vivia Biotech can significantly enhance AML drug profiling processes thanks to our access to biological samples from real patients.

Click  to learn more


Click  for custom assays in solid tumors

Click  for custom assays in hematological malignancies

Santiago Grisolia 2  
28760 . Madrid . Spain  
(+34) 91 129 3151  
admin@viviabiotech.com  
www.viviabiotech.com

## Vivia as Your Companion Diagnostic Clinical Trial in AML

- ✓ We have developed a precision medicine (PM) ex vivo test with 92% patients predicted to be sensitive and 75% overall survival at 3 years with a backbone first line treatment in AML patients
- ✓ Using this PM ex vivo test we have analyzed a novel Otsuka drug as CDx clinical trial
- ✓ A biomarker-driven design was used in a phase Ib clinical trial for the upfront identification and enrollment of AML patients based on the highest sensitivity to the Otsuka drug, discarding those hypothetically resistant ones and thus minimizing the likelihood of treatment failures.



## Vivia's Peer-Reviewed Published AML Data

As a result of the complete scientific support we offer to help our clients achieve their goals in AML drugs and compounds, we have collaborated in scientific articles and abstracts with several clients including Bristol-Myers Squibb, Otsuka, Acetylon, Molecular Partners, Tetrphase, Macrogenics, or Janssen, in addition to our own peer-reviewed published AML data.




## Overview


Vivia Biotech can significantly enhance AML drug profiling processes thanks to our access to biological samples from real patients.

Click  to learn more

Click  for custom assays in solid tumors

Click  for custom assays in hematological malignancies


Santiago Grisolia 2  
28760 . Madrid . Spain  
(+34) 91 129 3151  
admin@viviabiotech.com  
www.viviabiotech.com

 **Regular Article**

**MYELOID NEOPLASIA**  
**CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells**

**bjh** research paper


**Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with *ex vivo* chemosensitivity**

**ARTICLE**  **JLB** JOURNAL OF LEUKOCYTE BIOLOGY


**Ex-vivo drug testing predicts chemosensitivity in acute myeloid leukemia**

MEDICINE INTERNATIONAL 2: 7, 2022

**Biomarker-driven phase Ib clinical trial of OPB-111077 in acute myeloid leukemia**


 **PLOS ONE**

**Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia**


 **ELSEVIER**

Contents lists available at ScienceDirect  
**Leukemia Research**  
journal homepage: [www.elsevier.com/locate/leukres](http://www.elsevier.com/locate/leukres)

**A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients**

 **Mediterranean Journal of Hematology and Infectious Diseases**

**Original Article**  
**Differences in *ex-vivo* Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia**

 **frontiers in Oncology**

**Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy**